Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung Cancer

EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data

In the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.